Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Change in Accured Expenses: 2009-2024

Historic Change in Accured Expenses for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Dec 2024 value amounting to -$1.7 million.

  • Lineage Cell Therapeutics' Change in Accured Expenses rose 150.84% to $271,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$91,000, marking a year-over-year increase of 85.25%. This contributed to the annual value of -$1.7 million for FY2024, which is 26.75% up from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Change in Accured Expenses of -$1.7 million as of FY2024, which was up 26.75% from -$2.3 million recorded in FY2023.
  • Over the past 5 years, Lineage Cell Therapeutics' Change in Accured Expenses peaked at $21.6 million during FY2021, and registered a low of -$18.7 million during FY2022.
  • For the 3-year period, Lineage Cell Therapeutics' Change in Accured Expenses averaged around -$7.6 million, with its median value being -$2.3 million (2023).
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Change in Accured Expenses soared by 6,927.60% in 2021, and later slumped by 186.40% in 2022.
  • Yearly analysis of 5 years shows Lineage Cell Therapeutics' Change in Accured Expenses stood at $308,000 in 2020, then spiked by 6,927.60% to $21.6 million in 2021, then slumped by 186.40% to -$18.7 million in 2022, then surged by 87.73% to -$2.3 million in 2023, then climbed by 26.75% to -$1.7 million in 2024.